Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Sparano J, O'Neill A, Alpaugh K, Wolff AC, Northfelt DW, Dang CT, Sledge GW, Miller KD.

JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2574. [Epub ahead of print]

PMID:
30054636
2.

Preferred Clinician Communication About Stopping Cancer Screening Among Older US Adults: Results From a National Survey.

Schoenborn NL, Janssen EM, Boyd CM, Bridges JFP, Wolff AC, Pollack CE.

JAMA Oncol. 2018 Aug 1;4(8):1126-1128. doi: 10.1001/jamaoncol.2018.2100. No abstract available.

PMID:
29955796
3.

HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, McShane LM, Dowsett M.

J Oncol Pract. 2018 Jul;14(7):437-441. doi: 10.1200/JOP.18.00206. Epub 2018 Jun 19. No abstract available.

PMID:
29920138
4.

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.

Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, Del Mastro L, Ignatiadis M, Pritchard K, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Barrios CH, Baselga J, Moreno-Aspitia A, Piccart M, Gelber RD, de Azambuja E.

J Natl Cancer Inst. 2018 Jun 5. doi: 10.1093/jnci/djy094. [Epub ahead of print]

PMID:
29878225
5.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M.

J Clin Oncol. 2018 Jul 10;36(20):2105-2122. doi: 10.1200/JCO.2018.77.8738. Epub 2018 May 30.

PMID:
29846122
6.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M.

Arch Pathol Lab Med. 2018 May 30. doi: 10.5858/arpa.2018-0902-SA. [Epub ahead of print]

PMID:
29846104
7.

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

Denduluri N, Chavez-MacGregor M, Telli ML, Eisen A, Graff SL, Hassett MJ, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Somerfield MR, Trudeau ME, Wolff AC, Giordano SH.

J Clin Oncol. 2018 Aug 10;36(23):2433-2443. doi: 10.1200/JCO.2018.78.8604. Epub 2018 May 22.

PMID:
29787356
8.

A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.

Santa-Maria CA, Bardia A, Blackford AL, Snyder C, Connolly RM, Fetting JH, Hayes DF, Jeter SC, Miller RS, Nguyen A, Quinlan K, Rosner GL, Slater S, Storniolo AM, Wolff AC, Zorzi J, Henry NL, Stearns V.

Breast Cancer Res Treat. 2018 May 11. doi: 10.1007/s10549-018-4811-1. [Epub ahead of print]

PMID:
29752687
9.

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.

Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, Stella PJ, Burnette B, Telli M, Makower DF, Cheema P, Truica CI, Wolff AC, Soori GS, Haley B, Wassenaar TR, Goldstein LJ, Miller KD, Sparano JA.

J Clin Oncol. 2018 Jun 1;36(16):1556-1563. doi: 10.1200/JCO.2017.76.9331. Epub 2018 Apr 17.

PMID:
29664714
10.

Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors.

Jacobs MA, Macura KJ, Zaheer A, Antonarakis ES, Stearns V, Wolff AC, Feiweier T, Kamel IR, Wahl RL, Pan L.

Acad Radiol. 2018 Apr 4. pii: S1076-6332(18)30095-3. doi: 10.1016/j.acra.2018.02.010. [Epub ahead of print]

11.

First international TNBC conference meeting report.

Rida P, Ogden A, Ellis IO, Varga Z, Wolff AC, Traina TA, Hatzis C, Palmer JR, Ambrosone CB, Lehmann BD, Nanda R, Montgomery Rice V, Brawley OW, Torres MA, Rakha E, Aneja R.

Breast Cancer Res Treat. 2018 Jun;169(3):407-412. doi: 10.1007/s10549-018-4692-3. Epub 2018 Feb 8. Review.

PMID:
29417299
12.

Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.

Litvak A, Batukbhai B, Russell SD, Tsai HL, Rosner GL, Jeter SC, Armstrong D, Emens LA, Fetting J, Wolff AC, Silhy R, Stearns V, Connolly RM.

Cancer. 2018 May 1;124(9):1904-1911. doi: 10.1002/cncr.31260. Epub 2018 Jan 30.

PMID:
29381193
13.

Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.

Rosenstock AS, Niu J, Giordano SH, Zhao H, Wolff AC, Chavez-MacGregor M.

Cancer. 2018 Mar 1;124(5):899-906. doi: 10.1002/cncr.31144. Epub 2017 Dec 13.

PMID:
29236294
14.

Older Adults' Preferences for When and How to Discuss Life Expectancy in Primary Care.

Schoenborn NL, Lee K, Pollack CE, Armacost K, Dy SM, Xue QL, Wolff AC, Boyd C.

J Am Board Fam Med. 2017 Nov-Dec;30(6):813-815. doi: 10.3122/jabfm.2017.06.170067.

15.

Understanding the factors which promote registered nurses' intent to stay in emergency and critical care areas.

Van Osch M, Scarborough K, Crowe S, Wolff AC, Reimer-Kirkham S.

J Clin Nurs. 2018 Mar;27(5-6):1209-1215. doi: 10.1111/jocn.14167. Epub 2018 Jan 10.

PMID:
29148125
16.

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.

Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, Schiff R.

Breast Cancer Res Treat. 2018 Feb;167(3):731-740. doi: 10.1007/s10549-017-4533-9. Epub 2017 Nov 7.

PMID:
29110152
17.

Workplace continuing education for nurses caring for hospitalised older people.

Baumbusch J, Shaw M, Leblanc ME, Kjorven M, Kwon JY, Blackburn L, Lawrie B, Shamatutu M, Wolff AC.

Int J Older People Nurs. 2017 Dec;12(4). doi: 10.1111/opn.12161. Epub 2017 Jul 14.

18.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.

Krop I, Ismaila N, Andre F, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Wolff AC, Stearns V.

J Clin Oncol. 2017 Aug 20;35(24):2838-2847. doi: 10.1200/JCO.2017.74.0472. Epub 2017 Jul 10.

19.

Older Adults' Views and Communication Preferences About Cancer Screening Cessation.

Schoenborn NL, Lee K, Pollack CE, Armacost K, Dy SM, Bridges JFP, Xue QL, Wolff AC, Boyd C.

JAMA Intern Med. 2017 Aug 1;177(8):1121-1128. doi: 10.1001/jamainternmed.2017.1778.

20.

Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Breast Cancer: More Breakthroughs and an Embarrassment of Riches.

Griggs JJ, Wolff AC.

J Clin Oncol. 2017 Sep 1;35(25):2857-2859. doi: 10.1200/JCO.2017.73.9375. Epub 2017 Jun 3. No abstract available.

PMID:
28580883
21.

Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.

Gingras I, Holmes E, De Azambuja E, Nguyen DH, Izquierdo M, Anne Zujewski J, Inbar M, Naume B, Tomasello G, Gralow JR, Wolff AC, Harris L, Gnant M, Moreno-Aspitia A, Piccart MJ, Azim HA Jr.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djw331.

PMID:
28376188
22.

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.

Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim HA Jr, Fumagalli D, Sarp S, Wolff AC, Andersson M, Kroep J, Cufer T, Simon SD, Salman P, Toi M, Harris L, Gralow J, Keane M, Moreno-Aspitia A, Piccart-Gebhart M, de Azambuja E.

J Clin Oncol. 2017 May 1;35(13):1421-1429. doi: 10.1200/JCO.2016.69.7722. Epub 2017 Mar 13.

23.

Starting Out: qualitative perspectives of new graduate nurses and nurse leaders on transition to practice.

Regan S, Wong C, Laschinger HK, Cummings G, Leiter M, MacPhee M, Rhéaume A, Ritchie JA, Wolff AC, Jeffs L, Young-Ritchie C, Grinspun D, Gurnham ME, Foster B, Huckstep S, Ruffolo M, Shamian J, Burkoski V, Wood K, Read E.

J Nurs Manag. 2017 May;25(4):246-255. doi: 10.1111/jonm.12456. Epub 2017 Feb 27.

PMID:
28244181
24.

Reply to L. Del Mastro and A. Prat.

Denduluri N, Somerfield MR, Eisen A, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Telli ML, Trudeau ME, Wolff AC.

J Clin Oncol. 2017 Apr 1;35(10):1139. doi: 10.1200/JCO.2016.70.9758. Epub 2017 Jan 17. No abstract available.

PMID:
28095161
25.

Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board.

Dalton WB, Forde PM, Kang H, Connolly RM, Stearns V, Gocke CD, Eshleman JR, Axilbund J, Petry D, Geoghegan C, Wolff AC, Loeb DM, Pratilas CA, Meyer CF, Christenson ES, Slater SA, Ensminger J, Parsons HA, Park BH, Lauring J.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.16.00046. Epub 2017 May 31.

26.

Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.

Kim HS, Umbricht CB, Illei PB, Cimino-Mathews A, Cho S, Chowdhury N, Figueroa-Magalhaes MC, Pesce C, Jeter SC, Mylander C, Rosman M, Tafra L, Turner BM, Hicks DG, Jensen TA, Miller DV, Armstrong DK, Connolly RM, Fetting JH, Miller RS, Park BH, Stearns V, Visvanathan K, Wolff AC, Cope L.

J Clin Oncol. 2016 Dec 20;34(36):4390-4397. Epub 2016 Oct 31.

27.

Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.

Connolly RM, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater SA, Powers P, Wolff AC, Fetting JH, Brufsky A, Piekarz R, Ahuja N, Laird PW, Shen H, Weisenberger DJ, Cope L, Herman JG, Somlo G, Garcia AA, Jones PA, Baylin SB, Davidson NE, Zahnow CA, Stearns V.

Clin Cancer Res. 2017 Jun 1;23(11):2691-2701. doi: 10.1158/1078-0432.CCR-16-1729. Epub 2016 Dec 15.

28.

CDK4 and CDK6 Inhibition in Breast Cancer - A New Standard.

Wolff AC.

N Engl J Med. 2016 Nov 17;375(20):1993-1994. No abstract available.

PMID:
27959592
29.

Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.

Visvanathan K, Fackler MS, Zhang Z, Lopez-Bujanda ZA, Jeter SC, Sokoll LJ, Garrett-Mayer E, Cope LM, Umbricht CB, Euhus DM, Forero A, Storniolo AM, Nanda R, Lin NU, Carey LA, Ingle JN, Sukumar S, Wolff AC.

J Clin Oncol. 2017 Mar;35(7):751-758. doi: 10.1200/JCO.2015.66.2080. Epub 2016 Nov 21.

30.

Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer.

Parsons HA, Beaver JA, Cimino-Mathews A, Ali SM, Axilbund J, Chu D, Connolly RM, Cochran RL, Croessmann S, Clark TA, Gocke CD, Jeter SC, Kennedy MR, Lauring J, Lee J, Lipson D, Miller VA, Otto GA, Rosner GL, Ross JS, Slater S, Stephens PJ, VanDenBerg DA, Wolff AC, Young LE, Zabransky DJ, Zhang Z, Zorzi J, Stearns V, Park BH.

Clin Cancer Res. 2017 Jan 15;23(2):379-386. doi: 10.1158/1078-0432.CCR-16-1543. Epub 2016 Aug 3.

31.

Evolving Role of the Estrogen Receptor as a Predictive Biomarker: ESR1 Mutational Status and Endocrine Resistance in Breast Cancer.

Lauring J, Wolff AC.

J Clin Oncol. 2016 Sep 1;34(25):2950-2. doi: 10.1200/JCO.2016.68.4720. Epub 2016 Jul 5. No abstract available.

PMID:
27382095
32.

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR.

N Engl J Med. 2016 Jul 21;375(3):209-19. doi: 10.1056/NEJMoa1604700. Epub 2016 Jun 5.

33.

Still Refining Adjuvant Endocrine Therapy in Premenopausal Women: Not Too Much, Not Too Little.

Wolff AC, Rugo HS.

J Clin Oncol. 2016 Jul 1;34(19):2203-5. doi: 10.1200/JCO.2016.67.0463. Epub 2016 May 16. No abstract available.

PMID:
27185850
34.

Relationship Between Quality of Comorbid Condition Care and Costs for Cancer Survivors.

Frick KD, Snyder CF, Herbert RJ, Blackford AL, Neville BA, Wolff AC, Carducci MA, Earle CC.

J Oncol Pract. 2016 Jun;12(6):e734-45. doi: 10.1200/JOP.2015.006098. Epub 2016 May 10.

35.

Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.

Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, Dueck AC, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Perez EA, Piccart M, Azim HA Jr.

J Natl Cancer Inst. 2016 Apr 20;108(8). pii: djw037. doi: 10.1093/jnci/djw037. Print 2016 Aug.

36.

Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.

Denduluri N, Somerfield MR, Eisen A, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Telli ML, Trudeau ME, Wolff AC.

J Clin Oncol. 2016 Jul 10;34(20):2416-27. doi: 10.1200/JCO.2016.67.0182. Epub 2016 Apr 18.

PMID:
27091714
37.

A qualitative study of experienced nurses' voluntary turnover: learning from their perspectives.

Hayward D, Bungay V, Wolff AC, MacDonald V.

J Clin Nurs. 2016 May;25(9-10):1336-45. doi: 10.1111/jocn.13210. Epub 2016 Mar 16.

PMID:
26990238
38.

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU.

J Clin Oncol. 2016 Mar 20;34(9):945-52. doi: 10.1200/JCO.2015.63.0343. Epub 2016 Feb 1.

39.

Managing and mitigating conflict in healthcare teams: an integrative review.

Almost J, Wolff AC, Stewart-Pyne A, McCormick LG, Strachan D, D'Souza C.

J Adv Nurs. 2016 Jul;72(7):1490-505. doi: 10.1111/jan.12903. Epub 2016 Jan 29. Review.

PMID:
26822008
40.

Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907.

Lichtman SM, Cirrincione CT, Hurria A, Jatoi A, Theodoulou M, Wolff AC, Gralow J, Morganstern DE, Magrinat G, Cohen HJ, Muss HB.

J Clin Oncol. 2016 Mar 1;34(7):699-705. doi: 10.1200/JCO.2015.62.6341. Epub 2016 Jan 11.

41.

Improving an electronic system for measuring PROs in routine oncology practice.

Wu AW, White SM, Blackford AL, Wolff AC, Carducci MA, Herman JM, Snyder CF; PatientViewpoint Scientific Advisory Board.

J Cancer Surviv. 2016 Jun;10(3):573-82. doi: 10.1007/s11764-015-0503-6. Epub 2015 Dec 7.

42.

Cancer susceptibility genes and their potential implication regarding systemic therapy for early-stage breast cancer.

Karp JE, Wolff AC.

Cancer. 2016 Jan 15;122(2):178-80. doi: 10.1002/cncr.29613. Epub 2015 Dec 7. No abstract available.

43.

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA.

J Clin Oncol. 2016 Apr 1;34(10):1034-42. doi: 10.1200/JCO.2015.62.1797. Epub 2015 Nov 23.

44.

Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.

Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM.

JAMA Oncol. 2016 Jan;2(1):29-36. doi: 10.1001/jamaoncol.2015.3709.

45.

Long term side effects of adjuvant chemotherapy in patients with early breast cancer.

Tao JJ, Visvanathan K, Wolff AC.

Breast. 2015 Nov;24 Suppl 2:S149-53. doi: 10.1016/j.breast.2015.07.035. Epub 2015 Aug 20. Review.

46.

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).

Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele AD.

J Clin Oncol. 2015 Aug 20;33(24):2623-31. doi: 10.1200/JCO.2014.60.0353. Epub 2015 Jul 13.

47.

Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.

Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE.

J Clin Oncol. 2015 Jul 20;33(21):2353-60. doi: 10.1200/JCO.2015.60.9271. Epub 2015 Jun 15.

48.

A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay.

Gage MM, Rosman M, Mylander WC, Giblin E, Kim HS, Cope L, Umbricht C, Wolff AC, Tafra L.

Clin Breast Cancer. 2015 Dec;15(6):467-72. doi: 10.1016/j.clbc.2015.04.006. Epub 2015 Apr 23.

49.

Multiparametric and Multimodality Functional Radiological Imaging for Breast Cancer Diagnosis and Early Treatment Response Assessment.

Jacobs MA, Wolff AC, Macura KJ, Stearns V, Ouwerkerk R, El Khouli R, Bluemke DA, Wahl R.

J Natl Cancer Inst Monogr. 2015 May;2015(51):40-6. doi: 10.1093/jncimonographs/lgv014.

50.

Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).

Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM.

Breast Cancer Res Treat. 2015 Jun;151(3):589-96. doi: 10.1007/s10549-015-3426-z. Epub 2015 May 16.

Supplemental Content

Loading ...
Support Center